An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

To generate the following data from patients with early breast cancer treated with Aromasin® in the adjuvant setting in India.

• Efficacy of the treatment with Aromasin®
• Safety of the treatment with Aromasin®

NA The study was prematurely discontinued due to slow enrollment and keeping in mind the observational nature of the study. The decision to terminate had been taken on 16th June 2012 and the LSLV occured on 14th September, 2012. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.

Inclusion Criteria:

• Patients with early breast cancer receiving adjuvant therapy with Aromasin® will be eligible.

Exclusion Criteria:

• Patients presenting with in situ cancers, recurrent or metastatic breast cancer, or a 2nd primary will not be included.
• Patients with a known hypersensitivity to Exemestane or its metabolites will also not be included.